Sarah Meibusch

Sarah Meibusch is a dedicated and accomplished business leader with over 20 years of experience in enterprise-level management across diverse science and technology sectors, both in for-profit and not-for-profit settings.

Her career has seen her contribute to renowned organizations such as OneVentures, Shire Pharmaceuticals, University of Queensland, Beef CRC, Progen Pharmaceuticals, and Pyxis Genomics, where she has excelled in various leadership roles.

Sarah's expertise extends to negotiating intricate deals in corporate, government, and academic landscapes, involving research collaborations, licensing agreements, asset transactions, and strategic partnerships.

She possesses top-notch communication and interpersonal skills, allowing her to grasp complex ideas swiftly and communicate effectively to audiences with varying levels of expertise.

Sarah has been involved in significant corporate actions with NASDAQ and ASX listed companies, including mergers and acquisitions, fundraising initiatives, resolving shareholder conflicts, and steering clear of hostile takeover attempts.

In managing complex stakeholder relationships, she has adeptly navigated interactions with entities such as companies, investors, government bodies, and universities.

Sarah's educational background includes courses at the Australian Institute of Company Directors, an Executive Education Program at Harvard Business School, a Masters degree from Cornell University, and a Bachelor of Agricultural Science from The University of Queensland.

Throughout her career, Sarah has held key positions in various prestigious organizations, such as Principal at OneVentures, Non-Executive Director at Kira Biotech Pty Ltd, Board Observer and Alternate Director at Vaxxas Pty Ltd, and Non-Executive Director at Life Sciences Queensland Limited, among others.

Her extensive professional journey also involves roles like Investment Manager at OneVentures, Chief Operating Officer - Commercialisation at Beef CRC, Vice President of Business Development at Progen Pharmaceuticals, and Manager of Business Development at Pyxis Genomics.

Sarah Meibusch's commitment to leadership, strategic decision-making, and stakeholder engagement has established her as a multifaceted professional and a valuable asset in the fields of business, science, and technology.